Lymph Node Pathologic Grading Strategy

Launched by FUDAN UNIVERSITY · Dec 17, 2024

Keywords

ClinConnect Summary

This clinical trial, called the Lymph Node Pathologic Grading Strategy, is studying how certain patterns in cancer cells found in lymph nodes can help predict how well patients with lung adenocarcinoma (a type of lung cancer) will do after treatment. Researchers are particularly interested in understanding if higher grades of these patterns indicate worse outcomes for patients. The study is currently recruiting participants who have had surgery for lung adenocarcinoma between January 2011 and September 2021 at the Fudan University Shanghai Cancer Center.

To be eligible for the trial, patients must have been diagnosed with invasive lung adenocarcinoma and have their surgical samples available for study. However, patients with certain other types of lung cancer or incomplete information about their cancer mutations will not be included. Participants in the study can expect their medical records to be reviewed, and their lymph node samples analyzed to help researchers gain a better understanding of how these patterns affect cancer outcomes. This research could potentially lead to improved ways of predicting patient prognosis and tailoring treatment plans.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • From January 2011 to September 2021, we consecutively collected patients with invasive LUAD who underwent surgical resection at the Department of Thoracic Surgery, Fudan University Shanghai Cancer Center.
• Exclusion Criteria:
• • 1. adenocarcinoma in situ, minimally invasive adenocarcinoma, invasive mucinous adenocarcinoma, and other variants of adenocarcinoma;
• • 2. incomplete common driver mutation data;
• • 3. unavailable pathologic slides.